Status:
COMPLETED
Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Cervical Intraepithelial Neoplasia III
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of NIPP against CIN III lesions. * The aim of this project is to evaluate the potent...
Detailed Description
Cervical intraepithelial neoplasms (CIN), classified into severity levels CIN I to III, can be precursors to cervical cancer (CC), the world's third most common cancer in women (270,000 deaths / year)...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically confirmed CIN III
- Clearly visible transformation zone of the portio and margins of the lesions according to T1 / T2
- signed written consent
Exclusion
- Not fully visible transformation zone
- Indication of an invasive disease
- Serious cardiovascular diseases
- Patients who only want to undergo a LEEP excision
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04753073
Start Date
February 1 2021
End Date
June 30 2024
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Tuebingen, Department of Women's Health
Tübingen, Germany, 72076